Chemomab amends domestication merger terms ahead of planned Scipher deal

Bitget2026/09/30 20:08

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Amendment set a formula-based exchange ratio for Chemomab’s redomiciling into the U.S. ahead of its merger with Scipher.
Revision aims to fix the number of parent-company shares issued so the combined company has 10,000,000 shares outstanding at closing.
Terms keep the deal’s economics unchanged, including consideration and the relative ownership split between Chemomab and Scipher holders.
Transaction remains targeted for the fourth quarter of 2026, with the combined company expected to trade on Nasdaq under “SCIP.”
Post-close, the parent plans to rename itself Scipher Medicine Corporation, led by CEO Reginald Seeto; Chemomab CEO Adi Mor joins the board.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Chemomab Therapeutics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001178913-26-004676), on September 30, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Chemomab amends domestication merger terms ahead of planned Scipher deal

You may also like

Crypto prices